<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1E3015FF-23BB-4B73-8C80-84C53F33B745"><gtr:id>1E3015FF-23BB-4B73-8C80-84C53F33B745</gtr:id><gtr:name>Hospital for Sick Children, Toronto</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1971DE66-86B6-45D7-8CE0-39600A6FCCD6"><gtr:id>1971DE66-86B6-45D7-8CE0-39600A6FCCD6</gtr:id><gtr:name>Goethe University of Frankfurt am Main</gtr:name><gtr:address><gtr:line1>Max von Laue Str. 7</gtr:line1><gtr:line4>Frankfurt-am-Main</gtr:line4><gtr:postCode>60438</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:department>Centre for Reviews and Dissemination</gtr:department><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1E3015FF-23BB-4B73-8C80-84C53F33B745"><gtr:id>1E3015FF-23BB-4B73-8C80-84C53F33B745</gtr:id><gtr:name>Hospital for Sick Children, Toronto</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1971DE66-86B6-45D7-8CE0-39600A6FCCD6"><gtr:id>1971DE66-86B6-45D7-8CE0-39600A6FCCD6</gtr:id><gtr:name>Goethe University of Frankfurt am Main</gtr:name><gtr:address><gtr:line1>Max von Laue Str. 7</gtr:line1><gtr:line4>Frankfurt-am-Main</gtr:line4><gtr:postCode>60438</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6182DFD8-6A76-49E1-9F34-D7642CFAF378"><gtr:id>6182DFD8-6A76-49E1-9F34-D7642CFAF378</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>Stephen</gtr:otherNames><gtr:surname>Phillips</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800472"><gtr:id>14DBA42F-ADE0-4B8C-9350-4B83E623BBE1</gtr:id><gtr:title>Optimizing risk predictive strategies in febrile neutropenic episodes in children and young people with malignant disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800472</gtr:grantReference><gtr:abstractText>This project will develop a method of identifying children and young adult patients at low risk of harm when they present with febrile neutropenia, a complication of treatment for cancer. This may allow us to reduce the intensity or duration of the aggressive in-patient antibiotic treatment we currently use. The project will use individual patient data (IPD) pooled analysis, where the data from previously conducted studies are brought together and analysed to come to a more precise conclusion than any individual study could.

The project will form an international collaboration to collect the data, which will include researchers, doctors and parents. The analysis will try to find out if there are particular factors that would help us predict which children have the best outcomes. We will start by looking at the simplest information (such as the age of the child, or their diagnosis) and build in more complex data (such as specialized blood test results) to see if these make the prediction more accurate. The results of this analysis will be tested, and the potential economic effects estimated. 

The methods used in performing IPD analysis will also be investigated, advancing our understanding of how best to conduct such studies.</gtr:abstractText><gtr:technicalSummary>Aim:
To develop and evaluate an optimal risk stratification regime for paediatric and young adult patients with febrile neutropenia (FNP).

Objectives:
1. To systemically review and critically appraise existing risk stratification models for the prediction of the outcome of febrile neutropenic episodes in child/young adulthood
2. To form a collaborative group to centrally collect individual patient data (IPD) from cohort studies of febrile neutropenia in childhood
3. To undertake an IPD pooled analysis, using regression models to quantify the risk of adverse clinical outcomes according to clinical variables
4. To develop and explore issues around the use of pooled IPD analysis in the development of predictive models
5. To develop and validate a new risk prediction model
6. To undertake an analysis of the potential economic impact of applying the new model in clinical practice

Design:
Evidence synthesis of observational studies of febrile neutropenia in children using an IPD approach. 
 
Methodology:
1. Systematic review of existing paediatric FNP risk stratification guidelines.

2. IPD pooled analysis. An international collaboration will be established to facilitate the central collecting, validation and pooling of data from appropriate studies. The risk variables and outcomes selected for inclusion will be defined by literature review and consideration of the collaborative group. Should consensus fail to emerge, a formal process (Delphi questionnaires) will be used. The primary analysis will be based on the first recorded episode per patient to predict an absence of adverse outcomes (e.g. death, intensive care, or bacteremia). Subsequent episode data will be analysed to assess the independence of these data. The assessment will be by multivariate regression analysis, with variables entered after consideration of their clinical and statistical significance. The model will be tested by cross validation of intrinsic prognostic performance.

3. An analysis will be undertaken the potential economic impact of applying the new model in clinical practice.
 
4. Methodological refinement of the techniques of IPD pooled analysis will be undertaken (subject to the data obtained). The analyses may address the analysis of missing data, using different imputation models, the relative merits of prospective and retrospectively collected information, the comparison between episodic and patient-centred analyses and the use of categorical outcome variables. 

Scientific opportunities:
The development the methodology of IPD pooled analysis for prognostic models.

Medical opportunities:
The appropriate selection of individuals for who FNP therapy could be safely changed from lengthy in-patient spells to short out-patient based treatment, reducing costs and inconvenience.?</gtr:technicalSummary><gtr:fund><gtr:end>2013-10-12</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-13</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>217666</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Goethe University Frankfurt</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SIOP International FNP Guideline Group</gtr:description><gtr:id>5BA88B8B-D1BE-4C23-9E6D-E703E08D59C1</gtr:id><gtr:impact>Guideline: 2. Thomas Lehrnbecher, Robert Phillips, Sarah Alexander, Frank Alvaro, Fabianne Carlesse, Brian Fisher, Hana Hakim, Maria Santolaya, Elio Castagnola, Bonnie L Davis, L Lee Dupuis, Faith Gibson, Andreas H Groll, Aditya Gaur, Ajay Gupta, Rejin Kebudi, Antonio Petrilli, William J Steinbach, Milena Villarroel, Theoklis Zaoutis, and Lillian Sung. Guidelines for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem Cell Transplantation. Journal of Clinical Oncology 2012 [in press] 

Underpinning reviews:
Laura Rodriguez; Marie-Chantal Ethier; Bob Phillips; Thomas Lehrnbecher; John Doyle; Lillian Sung. Utility of peripheral blood cultures in patients with cancer and suspected blood stream infections: a systematic review Supportive Care in Cancer 2012 DOI:10.1007/s00520-012-1471-2

Arif Manji; Joseph Beyene; L. Lee Dupuis; Robert Phillips; Thomas Lehrnbecher; Lillian Sung. Outpatient and Oral Antibiotic Management of Low-Risk Febrile Neutropenia are Effective in Children - a Systematic Review of Prospective Trials. Supportive Care in Cancer 2012 ;20: 1135-1145 DOI: 10.1007/s00520-012-1425-8

Sung, L, Manji A, Beyene, J. Dupuis, L. Alexander, S. Phillips, R. Lehrnbecher T. Fluoroquinolones in Pediatric Fever and Neutropenia - a Systematic Review of Prospective Trials Pediatric Infectious Diseases Journal 2012 May;31:431-435</gtr:impact><gtr:outcomeId>AgbGspF7ZT2-2</gtr:outcomeId><gtr:partnerContribution>Undertook work on initial management and antifungal therapy.</gtr:partnerContribution><gtr:piContribution>Developed guideline methodology and led development of the risk stratification sections, and undertook meta-analysis for diagnostic and predictive sections.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital for Sick Children, Toronto</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Department of Haematology/Oncology</gtr:department><gtr:description>SIOP International FNP Guideline Group</gtr:description><gtr:id>320A8CF8-1D1A-4921-9D69-04A0C000DB1F</gtr:id><gtr:impact>Guideline: 2. Thomas Lehrnbecher, Robert Phillips, Sarah Alexander, Frank Alvaro, Fabianne Carlesse, Brian Fisher, Hana Hakim, Maria Santolaya, Elio Castagnola, Bonnie L Davis, L Lee Dupuis, Faith Gibson, Andreas H Groll, Aditya Gaur, Ajay Gupta, Rejin Kebudi, Antonio Petrilli, William J Steinbach, Milena Villarroel, Theoklis Zaoutis, and Lillian Sung. Guidelines for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem Cell Transplantation. Journal of Clinical Oncology 2012 [in press] 

Underpinning reviews:
Laura Rodriguez; Marie-Chantal Ethier; Bob Phillips; Thomas Lehrnbecher; John Doyle; Lillian Sung. Utility of peripheral blood cultures in patients with cancer and suspected blood stream infections: a systematic review Supportive Care in Cancer 2012 DOI:10.1007/s00520-012-1471-2

Arif Manji; Joseph Beyene; L. Lee Dupuis; Robert Phillips; Thomas Lehrnbecher; Lillian Sung. Outpatient and Oral Antibiotic Management of Low-Risk Febrile Neutropenia are Effective in Children - a Systematic Review of Prospective Trials. Supportive Care in Cancer 2012 ;20: 1135-1145 DOI: 10.1007/s00520-012-1425-8

Sung, L, Manji A, Beyene, J. Dupuis, L. Alexander, S. Phillips, R. Lehrnbecher T. Fluoroquinolones in Pediatric Fever and Neutropenia - a Systematic Review of Prospective Trials Pediatric Infectious Diseases Journal 2012 May;31:431-435</gtr:impact><gtr:outcomeId>AgbGspF7ZT2-1</gtr:outcomeId><gtr:partnerContribution>Undertook work on initial management and antifungal therapy.</gtr:partnerContribution><gtr:piContribution>Developed guideline methodology and led development of the risk stratification sections, and undertook meta-analysis for diagnostic and predictive sections.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Candlelighter's Newsletter Article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6418B6FF-A2D6-4318-91C7-31B0A7D56381</gtr:id><gtr:impact>Short (200 word) article in a Yorkshire Regional Patient/Carers Newsletter for children with cancer.

Approached by patient families to be thanked for interest in this problem.</gtr:impact><gtr:outcomeId>dMCbB7EbRQV</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>YouTube 'slidecast' to explain study to a non-professional audience</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7EC10BB9-70AE-4A3B-8C2E-349FBFE0F685</gtr:id><gtr:impact>A YouTube video explaining the risk stratification paper was made and viewed by professional and non-professional audiences, garnering some SoMe reponses priaing its clear explanation.</gtr:impact><gtr:outcomeId>5891b6071de6f1.76233241</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=32QstlBzgIk&amp;t=79s</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>7663</gtr:amountPounds><gtr:country>Canada</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Meetings, Planning &amp;amp; Dissemination Grant: Cancer Research</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>Canadian Institutes of Health Research</gtr:fundingOrg><gtr:id>8CE297BF-D8F2-4BAC-BD8B-18C9B47AF233</gtr:id><gtr:outcomeId>fmUCeeyw2ct0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cited in NICE Guideline</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>CG151 - Neutropenic Sepsis</gtr:guidelineTitle><gtr:id>2A1B5298-D64B-4564-8813-0C1A70C363D3</gtr:id><gtr:impact>Altered routine use of chest radiography in E&amp;amp;W.</gtr:impact><gtr:outcomeId>RBJWJQDJ2Zg</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.nice.org.uk/CG151</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in International FNP Guideline</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Guidelines for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem Cell Transplantation.</gtr:guidelineTitle><gtr:id>059FFF1E-75FA-4A11-B30C-00799870CF21</gtr:id><gtr:outcomeId>Tyd5x4YepSf</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/22987086</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CDR cited in JOP Paper</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>A7F2EB1F-69D1-4CF2-83C7-6739F964A422</gtr:id><gtr:outcomeId>UCbujk3MGs8</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CXR cited in COID reveiw</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>9A34F6F1-8E14-4AD0-8F83-24113458A878</gtr:id><gtr:outcomeId>VSkJeT2GhSQ</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type><gtr:url>http://journals.lww.com/co-infectiousdiseases/Abstract/2012/06000/Rationalizing_the_approach_to_children_with_fever.5.aspx</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Clinical Lead for the NICE Neutropenic Sepsis GDG</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6737B08C-2691-41FA-A7A2-EAE2412266C2</gtr:id><gtr:impact>Appointed Clinical Lead for the NICE Neutropenic Sepsis guideline; influenced national policy in the area (E&amp;amp;W)</gtr:impact><gtr:outcomeId>RUEsXTCHnnV</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CDR cited in CPEM</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>8F439A57-D1B5-42B6-A09E-FE8669F59230</gtr:id><gtr:outcomeId>mh6Hg6f1RVb</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type><gtr:url>http://jco.ascopubs.org/content/30/35/4427.short</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>962C6614-B726-4705-88E2-C2CAC6B5CC1C</gtr:id><gtr:title>Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7924d06e4cc434d47f60751c6fecfb33"><gtr:id>7924d06e4cc434d47f60751c6fecfb33</gtr:id><gtr:otherNames>Phillips RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>585d675408c0d7.77426730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CF8FA16-72D7-4FC7-8F78-8A340569313E</gtr:id><gtr:title>The reporting of outcomes in studies of fever and neutropenia in children with cancer: time for consensus.</gtr:title><gtr:parentPublicationTitle>Pediatric blood &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60a462e35c76c44ea07706025bdb3058"><gtr:id>60a462e35c76c44ea07706025bdb3058</gtr:id><gtr:otherNames>Haeusler GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1545-5009</gtr:issn><gtr:outcomeId>doi_12719__pbc_24662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3925B68F-D9A7-4AE3-9921-2A762E870768</gtr:id><gtr:title>Systematic review and meta-analysis of the value of clinical features to exclude radiographic pneumonia in febrile neutropenic episodes in children and young people.</gtr:title><gtr:parentPublicationTitle>Journal of paediatrics and child health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff8e811c5dae5e9ecc52ec4042d2d493"><gtr:id>ff8e811c5dae5e9ecc52ec4042d2d493</gtr:id><gtr:otherNames>Phillips B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1034-4810</gtr:issn><gtr:outcomeId>rBwV29MwnaA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C202A988-C83F-407B-A705-BDEF8567DF11</gtr:id><gtr:title>Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol).</gtr:title><gtr:parentPublicationTitle>Systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7924d06e4cc434d47f60751c6fecfb33"><gtr:id>7924d06e4cc434d47f60751c6fecfb33</gtr:id><gtr:otherNames>Phillips RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2046-4053</gtr:issn><gtr:outcomeId>pm_12719_29_22588015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4DA1636-BA5B-4A49-80CC-4E41F2CED9D7</gtr:id><gtr:title>'Cross hairs' plots for diagnostic meta-analysis.</gtr:title><gtr:parentPublicationTitle>Research synthesis methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff8e811c5dae5e9ecc52ec4042d2d493"><gtr:id>ff8e811c5dae5e9ecc52ec4042d2d493</gtr:id><gtr:otherNames>Phillips B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1759-2879</gtr:issn><gtr:outcomeId>bdfTrTMh6wG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0538BF3-6A0B-4F5A-B10E-94DE054E9078</gtr:id><gtr:title>Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7924d06e4cc434d47f60751c6fecfb33"><gtr:id>7924d06e4cc434d47f60751c6fecfb33</gtr:id><gtr:otherNames>Phillips RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12719_29_22693615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B256D9B-F394-47CA-AE14-16482F33BF79</gtr:id><gtr:title>Utility of peripheral blood cultures in patients with cancer and suspected blood stream infections: a systematic review.</gtr:title><gtr:parentPublicationTitle>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f344dc538b3fb400623f1a10a4b03b8b"><gtr:id>f344dc538b3fb400623f1a10a4b03b8b</gtr:id><gtr:otherNames>Rodr?guez L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0941-4355</gtr:issn><gtr:outcomeId>pm_12719_29_22544224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08BB26E3-B9A6-4B48-9ECF-F7847080E9EA</gtr:id><gtr:title>Variation in practice remains in the UK management of paediatric febrile neutropenia.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af8ddc33e42acbdde0aeb90223c701a8"><gtr:id>af8ddc33e42acbdde0aeb90223c701a8</gtr:id><gtr:otherNames>Herd F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>5891b4c7e8cdf1.73627091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32169FA6-5DBA-4774-921A-BB72A267CB93</gtr:id><gtr:title>An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60a462e35c76c44ea07706025bdb3058"><gtr:id>60a462e35c76c44ea07706025bdb3058</gtr:id><gtr:otherNames>Haeusler GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>pm_540e15de15d1c7225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3849979B-31D8-494E-AED6-DA5CBA1C7BEC</gtr:id><gtr:title>Prospective cohort study of procalcitonin levels in children with cancer presenting with febrile neutropenia.</gtr:title><gtr:parentPublicationTitle>BMC pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88657c4dffb9fbf5253c352e9bd706a"><gtr:id>f88657c4dffb9fbf5253c352e9bd706a</gtr:id><gtr:otherNames>Hemming V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2431</gtr:issn><gtr:outcomeId>5891b4c7abe6f2.60021382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B527E5F1-64EA-4CE3-B771-2B78D373FECB</gtr:id><gtr:title>Core outcomes and definitions for pediatric fever and neutropenia research: a consensus statement from an international panel.</gtr:title><gtr:parentPublicationTitle>Pediatric blood &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60a462e35c76c44ea07706025bdb3058"><gtr:id>60a462e35c76c44ea07706025bdb3058</gtr:id><gtr:otherNames>Haeusler GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1545-5009</gtr:issn><gtr:outcomeId>56b08987bb0178.43484474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A9CF84B-72B5-44BE-BE58-BBE381B79427</gtr:id><gtr:title>Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7924d06e4cc434d47f60751c6fecfb33"><gtr:id>7924d06e4cc434d47f60751c6fecfb33</gtr:id><gtr:otherNames>Phillips RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>pm_12719_29_22257704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>731DBB42-57E4-4A09-878D-464F75592C0D</gtr:id><gtr:title>Rationalizing the approach to children with fever in neutropenia.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17d4ea3bf8e3c2b3dba9d2b5d0a28f05"><gtr:id>17d4ea3bf8e3c2b3dba9d2b5d0a28f05</gtr:id><gtr:otherNames>Ammann RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>pm_12719_29_22395759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B86402A-FA4D-4D0E-A1DC-68BCAA11E9A1</gtr:id><gtr:title>Ethical and regulatory considerations in the use of individual participant data for studies of disease prediction.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff8e811c5dae5e9ecc52ec4042d2d493"><gtr:id>ff8e811c5dae5e9ecc52ec4042d2d493</gtr:id><gtr:otherNames>Phillips B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>pm_12719_29_23661573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C662FF6-1F88-4904-B2AD-AF58A6A03835</gtr:id><gtr:title>Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff8e811c5dae5e9ecc52ec4042d2d493"><gtr:id>ff8e811c5dae5e9ecc52ec4042d2d493</gtr:id><gtr:otherNames>Phillips B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>TKQWeR7RCwQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8879E488-ABB4-4FFE-BFC4-F1AE2057CAF4</gtr:id><gtr:title>Systematic review of reduced therapy regimens for children with low risk febrile neutropenia.</gtr:title><gtr:parentPublicationTitle>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/263d337c9b689bdd8f73e9e799f6165a"><gtr:id>263d337c9b689bdd8f73e9e799f6165a</gtr:id><gtr:otherNames>Morgan JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0941-4355</gtr:issn><gtr:outcomeId>56b089f7388509.68145219</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800472</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>B7F5A9CA-62C7-4E68-A2B2-3D6CCA85E16B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>7.3  Management and decision making</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>